Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-PD-1 antibody AI-025/anti-CTLA-4 antibody ONC-392 combination formulation AI-061

A 1:1 fixed dose combination formulation composed of the two monoclonal antibodies AI-025, a monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), and gotistobart, a pH-sensitive immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4; CD152), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration of anti-PD-1 antibody AI-025/anti-CTLA-4 antibody ONC-392 combination formulation AI-061, AI-025 targets, binds to and inhibits PD-1 and ONC-392 targets, binds to and inhibits CTLA-4. This inhibits the PD-1- and CTLA-4-mediated downregulation of T-cell activation and proliferation. This restores immune function and activates a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. Both PD-1 and CTLA-4 are selectively expressed on TILs in the tumor microenvironment (TME) and negatively regulate the activation and effector functions of T cells. They play key roles in the downregulation of the immune system and tumor evasion from host immunity. Dual checkpoint blockade of PD-1 and CTLA-4 enhances T cell activation and proliferation more than the blockade of either immune checkpoint receptor alone. PD-1, a transmembrane protein in the immunoglobulin superfamily (IgSF) expressed on T cells, functions as an immune checkpoint that negatively regulates T-cell activation and effector function when activated by its ligands programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) or 2 (PD-L2; CD273); it plays an important role in tumor evasion from host immunity. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily (IgSF), plays a key role in the downregulation of the immune system.
Synonym:AI-025/Gotistobart combination AI-061
AI-025/ONC-392
anti-PD-1 antibody AI-025/anti-CTLA-4 antibody ONC-392 combination AI-061
anti-PD-1 antibody AI-025/Gotistobart combination AI-061
co-formulation AI-025/ONC-392
monoclonal antibodies combination formulation AI-061
ONC-392/AI-025
Code name:AI 061
AI-061
AI061
Search NCI's Drug Dictionary